- Home
- OPFI vs CKPT Comparison
OPFI vs CKPT Comparison
Compare OPFI & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- CKPT
- Stock Information
- Founded
- OPFI 2009
- CKPT 2014
- Country
- OPFI United States
- CKPT United States
- Employees
- OPFI N/A
- CKPT N/A
- Industry
- OPFI Finance: Consumer Services
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- CKPT Health Care
- Exchange
- OPFI Nasdaq
- CKPT Nasdaq
- Market Cap
- OPFI 174.4M
- CKPT 151.9M
- IPO Year
- OPFI N/A
- CKPT 2017
- Fundamental
- Price
- OPFI $12.76
- CKPT $2.91
- Analyst Decision
- OPFI Buy
- CKPT Strong Buy
- Analyst Count
- OPFI 2
- CKPT 2
- Target Price
- OPFI $7.50
- CKPT $13.50
- AVG Volume (30 Days)
- OPFI 1.9M
- CKPT 956.5K
- Earning Date
- OPFI 03-06-2025
- CKPT 11-12-2024
- Dividend Yield
- OPFI N/A
- CKPT N/A
- EPS Growth
- OPFI 775.86
- CKPT N/A
- EPS
- OPFI 0.38
- CKPT N/A
- Revenue
- OPFI $260,661,000.00
- CKPT $47,000.00
- Revenue This Year
- OPFI N/A
- CKPT N/A
- Revenue Next Year
- OPFI $6.51
- CKPT $172,016.02
- P/E Ratio
- OPFI $31.87
- CKPT N/A
- Revenue Growth
- OPFI 23.85
- CKPT N/A
- 52 Week Low
- OPFI $2.35
- CKPT $1.38
- 52 Week High
- OPFI $12.50
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- OPFI 75.11
- CKPT 40.05
- Support Level
- OPFI $11.45
- CKPT $2.68
- Resistance Level
- OPFI $12.50
- CKPT $3.42
- Average True Range (ATR)
- OPFI 1.03
- CKPT 0.21
- MACD
- OPFI 0.31
- CKPT -0.04
- Stochastic Oscillator
- OPFI 99.49
- CKPT 25.69
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.